A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Conditions: Generalized Myasthenia Gravis Interventions: Biological: Efgartigimod IV; Other: Placebo IV Sponsors: argenx Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials